BioSpace News Archive

NKGen Biotech Inc. (Nasdaq: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, today announced its financial results for the third quarter ended September 30, 2023, and provided business highlights.

Retractable Technologies, Inc. reports that its loss from operations was $8.7 million for the first nine months of 2023 and that it had an operating loss of $936 thousand for the third quarter of 2023, as compared to an operating income for the same periods last year of $7.0 million for the first nine months of 2022 and an operating loss of $691 thousand for the third quarter of 2022.

NeuroOne Medical Technologies Corporation announced that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer.

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.

InnoCare Pharma announced that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology Annual Meeting on December 9-12, 2023 in San Diego, California, United States.

Scientific Industries, Inc., a life sciences tool provider and a developer of digitally simplified bioprocessing products, reported financial results for the three and nine-month periods ended September 30, 2023.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.

PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, provides a business and financial update for the third quarter of 2023.

Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Miromatrix Medical Inc. (Nasdaq: MIRO) (the “Company”), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported third quarter 2023 financial results.